Vaccine adjuvant composition for treatment or prevention of swine infectious diseases

A technology for infectious diseases and vaccine adjuvants, which is applied in the field of vaccine adjuvant compositions for the treatment or prevention of porcine infectious diseases, can solve problems such as the limited number of adjuvants, reduce usage, reduce side effects, and improve immune efficacy Effect

Active Publication Date: 2013-05-08
PU LIKE BIO ENG +2
View PDF11 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the number of adjuvants th...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine adjuvant composition for treatment or prevention of swine infectious diseases
  • Vaccine adjuvant composition for treatment or prevention of swine infectious diseases
  • Vaccine adjuvant composition for treatment or prevention of swine infectious diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1, the vaccine adjuvant composition containing porcine circovirus antigen and vaccine thereof

[0040] 1. Preparation of porcine circovirus antigen

[0041] 1.1 Preparation of bacteria (virus) species for production

[0042] The preparation of porcine circovirus type 2 SH: virus seed is used MEM medium ( Invitrogen Company) was diluted 10 times, inoculated in PK15 (ATCC, preservation number is CCL-33) cell culture by 5% volume, adsorbed at 37°C for 30 minutes, added D-glucosamine containing 4% calf serum and 2mmol / L MEM cell maintenance solution of hydrochloric acid, cultivated at 37°C for 4 days, freeze-thawed 2-3 times, harvested the virus, and the virus titer was 10 6.5 TCID 50 / ml.

[0043] 1.2 Culture preparation of virus liquid or bacterial liquid

[0044] The preparation of porcine circovirus type 2 SH strain virus liquid: the method of cell culture in roller bottles. For the PK15 cells (purchased from ATCC) covered with a single layer, the cell...

Embodiment 2

[0083] The immune effect contrast of embodiment 2, test example 1-10

[0084] 1. Experimental animals and grouping

[0085] 60 PCV2 ELISA antibody-negative healthy female clean-grade Balb / c mice aged 5-6 weeks (PCV2 ELISA antibody titer not higher than 1:50) were used and divided into 12 groups, 5 mice in each group. According to Table 1, 0.2ml of each animal was immunized, and the second inoculation was carried out by the same route and dose two weeks later; the blank control was inevitable. The mice in each group were kept in isolation for observation. Blood was collected 3 weeks after the second immunization, the serum was separated, and the PCV2 ELISA antibody titer in the serum was determined. Serum samples from 5 mice were mixed and diluted 6400X, 12800X, and each dilution was repeated for 2 wells

[0086] Table 2 Test grouping and treatment table

[0087]

[0088] 2. Mouse antibody detection

[0089] Use PCV2 ELISA antibody detection method: use PCV2 recombinant...

Embodiment 3

[0113] Embodiment 3, the vaccine adjuvant composition containing swine mycoplasma pneumonia antigen and vaccine thereof

[0114] 1. Preparation of Mycoplasma Pneumonia Antigen

[0115] Strains: Mycoplasma suis pneumonia was selected as strain MR48, and it was preserved in the General Microbiology Center of China Committee for the Collection of Microorganisms on September 19, 2006. The abbreviation of the preservation unit: CGMCC, the preservation number: CGMCCNo.1816, the classification name: pig Mycoplasma pneumoniae, the English name is Mycoplasma hyopneumoniae, address of depository unit: No. 1 courtyard, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences 1. Propagation of first-class seeds: get Mycoplasma hyopneumoniae MR48 strain freeze-dried bacterial classification respectively, use Dilute the liquid medium, inoculate it on a solid medium plate, culture it at 37°C for 7-10 days, select a well-growing colony, and use it ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Titeraaaaaaaaaa
Login to view more

Abstract

The present invention provides a vaccine adjuvant composition for treatment or prevention of swine infectious diseases. The vaccine adjuvant composition contains a milkvetch root extract, a polymer and an antigen component, or contains a milkvetch root extract, a polymer, cyclodextrin and an antigen component. The vaccine adjuvant can be combined with porcine circovirus antigen or mycoplasma hyopneumoniae antigen so as to substantially improve vaccine immune efficacy, wherein the original immune efficacy can be achieved after reducing the amount of the vaccine to the half of the amount of the original antigen; and test results of the vaccine adjuvant with a plurality of doses show that: the vaccine adjuvant does not have a significant side effect, and provides significantly reduced side effect compared with the commonly used oil phase adjuvant.

Description

technical field [0001] The invention relates to a vaccine adjuvant, in particular to a vaccine adjuvant composition containing astragalus polysaccharide and its polymer for treating or preventing porcine infectious diseases. Background technique [0002] Vaccine adjuvants are used for two purposes: they slow the release of antigens from the injection site, and they stimulate the immune system. Traditional vaccines usually consist of crude preparations of inactivated or killed or modified live pathogenic microorganisms. Impurities associated with cultures of these pathogenic microorganisms can act as adjuvants to enhance the immune response. Adding an adjuvant, however, allows a smaller dose of antigen to be used to stimulate a similar immune response, reducing the cost of vaccine manufacture. Thus, the efficacy of certain injectable vaccines can be significantly increased when the vaccine is combined with an adjuvant. [0003] Many factors must be considered when selectin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61K39/12A61K39/02A61P31/20A61P31/04
Inventor 张许科孙进忠
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products